The latest from HNF: research updates, patient stories, advocacy wins, events, and CMT community news.
No matches for .
Showing 1 to 12 of 316
September 17, 2026
CureCMT (HNF) brought hearing testing on-site at the 2026 Clinical Trial Readiness Summit, a first for the CMT community. About half of those screened showed some hearing loss, matching what 445 GRIN registry responses had been saying for years.
September 16, 2026
On August 4, CureCMT (HNF) led a Patient-Focused Listening Session with the FDA dedicated entirely to CMT-SORD. Six patients and family members told the agency what the disease costs them, and what a treatment would give back.
May 21, 2026
A South Korean biotech, ENCell, has dosed the first patient in a Phase 2a trial of EN001, a stem cell therapy aimed at the myelin damage behind CMT1A.
May 21, 2026
HNF is hosting an FDA Patient Listening Session for the CMT-SORD community on August 4, giving patients and caregivers a direct line to the agency at a critical moment for the subtype.
May 21, 2026
Over 200 attendees made the 2026 CMT Summit our biggest gathering yet. Thank you to our sponsors, speakers, research participants, and every member of the community who came.
May 21, 2026
If you have a genetic report related to your CMT diagnosis, uploading it to GRIN is one of the most direct contributions you can make to CMT research today. Even negative or inconclusive reports belong.
May 18, 2026
May 18, 2026
May 18, 2026
May 18, 2026
May 1, 2026
Changes how this site looks for you, and are saved on this device.
We use cookies to see how the site is used (analytics) and to power embedded videos and podcasts. Analytics stay off until you say yes. See our privacy policy.
Be the first to know
Research moves fast. Add your number and we will text you the things that matter most: new treatment news, trial openings, and ways to take part before they fill up.
